Seneca Biopharma, Inc. logo
Seneca Biopharma, Inc. SNCA

Seneca Biopharma, Inc. Market Cap 2011-2026 | SNCA

As of April 06, 2026 Seneca Biopharma, Inc. has a market cap of $ 28.7 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Seneca Biopharma, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
538 K 425 K 1.06 M 4.01 M 4.12 M 11.8 M 45 M 39 M 12.3 M 8.06 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
45 M 425 K 12.6 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
Aquestive Therapeutics Aquestive Therapeutics
AQST
467 M $ 4.14 0.36 % $ 443 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
217 M $ 8.41 4.73 % $ 230 M israelIsrael
Ardelyx Ardelyx
ARDX
1.62 B $ 6.06 1.94 % $ 1.46 B usaUSA
argenx SE argenx SE
ARGX
13.8 B $ 752.35 0.79 % $ 25 B niderlandNiderland
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
3.44 B $ 23.83 0.85 % $ 3.03 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
15.8 M $ 2.65 -1.12 % $ 16.6 M usaUSA
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
168 B - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
BioCardia BioCardia
BCDA
8.07 M $ 1.2 -0.04 % $ 8 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
1.72 B $ 9.6 6.37 % $ 1.98 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
8.59 B $ 9.48 -3.27 % $ 613 M usaUSA
BioVie BioVie
BIVI
2.44 M $ 1.45 2.09 % $ 2.14 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
22.1 M - - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
1.35 B $ 2.32 4.98 % $ 908 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
11.7 B $ 56.49 1.78 % $ 10.8 B usaUSA
BioNTech SE BioNTech SE
BNTX
62.9 B $ 92.3 1.23 % $ 27.2 B germanyGermany
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
71.4 M - 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
38.2 M - 10.36 % $ 9.8 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
291 M $ 3.04 1.54 % $ 259 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
15.4 M $ 1.16 -2.12 % $ 14.2 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 4.54 9.54 % $ 683 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
283 M $ 3.2 7.94 % $ 322 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
3.16 B $ 3.21 4.56 % $ 6.98 B israelIsrael
Aravive Aravive
ARAV
60.4 M - -13.39 % $ 1.45 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
999 M $ 19.97 2.94 % $ 1.78 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
9.48 M - -39.0 % $ 4.57 M usaUSA
Codexis Codexis
CDXS
111 M $ 1.97 7.97 % $ 172 M usaUSA
Cerus Corporation Cerus Corporation
CERS
496 M $ 1.91 2.42 % $ 364 M usaUSA
Cullinan Management Cullinan Management
CGEM
898 M $ 15.4 6.72 % $ 928 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
226 M $ 1.75 0.87 % $ 205 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
81.2 B - - $ 96.9 B britainBritain